Abstract
In October UK patients who had cardiovascular events while taking rofecoxib lost the right to fight Merck in the US for compensation. But researchers and journals can still benefit from this case if they learn from the mistakes, write Harlan Krumholz and colleagues
MeSH terms
-
Cardiovascular Diseases / chemically induced*
-
Compensation and Redress / legislation & jurisprudence*
-
Cyclooxygenase 2 Inhibitors / adverse effects*
-
Drug Industry / legislation & jurisprudence*
-
Humans
-
Interprofessional Relations
-
Lactones / adverse effects*
-
Risk Factors
-
Scientific Misconduct / legislation & jurisprudence
-
Sulfones / adverse effects*
-
Time Factors
-
United Kingdom
-
United States
Substances
-
Cyclooxygenase 2 Inhibitors
-
Lactones
-
Sulfones
-
rofecoxib